|
G |
Arf6 |
ADP-ribosylation factor 6 |
multiple interactions |
ISO |
2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]] |
CTD |
PMID:10931844 |
|
NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases activity |
ISO |
2,3-Diphosphoglycerate results in decreased activity of BGLAP protein |
CTD |
PMID:16857255 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Pld1 |
phospholipase D1 |
decreases activity |
ISO |
2,3-Diphosphoglycerate results in decreased activity of PLD1 protein |
CTD |
PMID:16857255 |
|
NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Sts |
steroid sulfatase |
multiple interactions |
ISO |
2,3-Diphosphoglycerate inhibits the reaction [Tretinoin results in increased activity of STS protein] |
CTD |
PMID:16178010 |
|
NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402
|
|
|
G |
Arf6 |
ADP-ribosylation factor 6 |
multiple interactions |
ISO |
2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]] |
CTD |
PMID:10931844 |
|
NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases activity |
ISO |
2,3-Diphosphoglycerate results in decreased activity of BGLAP protein |
CTD |
PMID:16857255 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Pld1 |
phospholipase D1 |
decreases activity |
ISO |
2,3-Diphosphoglycerate results in decreased activity of PLD1 protein |
CTD |
PMID:16857255 |
|
NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Sts |
steroid sulfatase |
multiple interactions |
ISO |
2,3-Diphosphoglycerate inhibits the reaction [Tretinoin results in increased activity of STS protein] |
CTD |
PMID:16178010 |
|
NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402
|
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
EXP |
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-phosphoglycerate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|